News | November 29, 2022
Fredun Pharmaceuticals signs two large contracts
Fredun received one-year contract worth Rs. 65 crores from a Southeast Asian country for Pharma exports
Fredun received one-year contract worth Rs. 65 crores from a Southeast Asian country for Pharma exports
The product is expected to be launched by Q4 FY23.
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
The acquisition is for an enterprise value of Rs. 218 crores
Revenue is up 23% whereas Profit After Tax expands 29% for the company
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
The objective of this study is to evaluate the efficacy of ASC22 (Envafolimab) combined with Chidamide on the viral reservoirs of latently infected cells in HIV patients.
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Subscribe To Our Newsletter & Stay Updated
